No Data
No Data
Roth MKM Resumes Coverage of LeMaitre With Buy Rating
Navigating 4 Analyst Ratings For LeMaitre Vascular
LeMaitre Vascular (NASDAQ:LMAT) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table summarizes their recent
Express News | Roth MKM Reinstates Buy on LeMaitre Vascular, Announces $100 Price Target
LeMaitre Vascular Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 26.95% Roth MKM → $100 Reinstates → Buy 05/03/2024 0.29% Barrington Research $69 → $79 Maintain
Lemaitre Vascular's Dominant Market Position and Growth Prospects Garner 'Buy' Rating
LeMaitre to Present at the Jefferies Global Healthcare Conference
BURLINGTON, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that George W. LeMaitre, Chairman & CEO, will present at the 2024 Jefferies Global Healthcare Conference on
No Data